| Literature DB >> 27516904 |
A B Ivanova1, D I Batovska1, I T Todorova1, B A Stamboliyska1, J Serly2, J Molnar2.
Abstract
Based on the structure of three previously established lead compounds, fifteen selected chalcones were synthesized and evaluated for their multidrug resistance (Entities:
Year: 2010 PMID: 27516904 PMCID: PMC4970649 DOI: 10.1155/2011/530780
Source DB: PubMed Journal: Int J Med Chem ISSN: 2090-2077
| FICA = ID50A in combination/ID50A alone | FIX = FICA + FICB |
| FICB = ID50B in combination/ID50B alone | FIX = 0.5–1, additive effect |
| ID = inhibitory dose | FIX < 0.5, synergism |
| FIC = fractional inhibitory concentration | FIX = 1 ÷ 2, indifferent effect |
| FIX = fractional inhibitory index | FIX > 2, antagonism |
Substitution pattern and calculated log P values of the chalcones studied for their MDR reversal activity.
|
| ||||
|
| ||||
| Compound | Methoxylation pattern of ring A | R | log | Referencea |
|
| ||||
|
| 3′,4′,5′- | –Cl | 4.0 | [ |
|
| 3′,4′,5′- | –N(CH3)2 | 3.5 | [ |
|
| 3′,4′,5′- | –OCH3 | 3.3 | [ |
|
| 2′,3′,4′- | –Cl | 4.0 | [ |
|
| 2′,3′,4′- | –N(CH3)2 | 3.5 | [ |
|
| 2′,3′,4′- | –OCH3 | 3.3 | [ |
|
| 2′,4′,6′- | –Cl | 4.0 | [ |
|
| 2′,4′,6′- | –N(CH3)2 | 3.5 | [ |
|
| 2′,4′,6′- | –OCH3 | 3.3 | [ |
|
| 3′,4′- | –Cl | 4.2 | — |
|
| 3′,4′- | –N(CH3)2 | 3.7 | [ |
|
| 3′,4′- | –OCH3 | 3.4 | [ |
|
| 2′,4′- | –Cl | 4.2 | [ |
|
| 2′,4′- | –N(CH3)2 | 3.7 | [ |
|
| 2′,4′- | –OCH3 | 3.4 | [ |
|
| 2′,5′- | –Cl | 4.2 | — |
|
| 2′,5′- | –N(CH3)2 | 3.7 | [ |
|
| 2′,5′- | –OCH3 | 3.4 | [ |
aChalcones reported by other sources.
Reversal of MDR by chalcones 4–18 on mouse lymphoma cell line L 5178 T—dose-response experiments.
| Compound | Concentration [ | Fluorescence activity (ratio) |
|---|---|---|
| Verapamil | 5.2 | 4.94 |
|
| 4 | 40.37a |
| 40 | 26.63a | |
|
| 4 | 5.54a |
| 40 | 33.16a | |
|
| 4 | 2.24a |
| 40 | 65.54a | |
|
| 4 | 2.93 |
| 40 | 36.40 | |
|
| 4 | 10.04 |
| 40 | 49.28 | |
|
| 4 | 2.86 |
| 40 | 34.92 | |
|
| 4 | 9.84 |
| 40 | 29.11 | |
|
| 4 | 9.68 |
| 40 | 22.35 | |
|
| 4 | 3.57 |
| 40 | 12.26 | |
|
| 4 | 41.65 |
| 40 | 48.37 | |
|
| 4 | 5.04 |
| 40 | 83.80 | |
|
| 4 | 2.84 |
| 40 | 47.14 | |
|
| 4 | 2.59 |
| 40 | 39.93 | |
|
| 4 | 9.81 |
| 40 | 22.28 | |
|
| 4 | 1.73 |
| 40 | 37.85 | |
|
| 4 | 1.54 |
| 40 | 16.64 | |
|
| 4 | 1.81 |
| 40 | 16.47 | |
|
| 4 | 2.48 |
| 40 | 25.40 | |
| DMSO control | 20 | 1.23 |
aThe FAR values of chalcones 1, 2, and 3 were determined previously [8].
Figure 1Influence of the substituent pattern in rings A and B on the MDR reversal of chalcones 1–18 on mouse lymphoma cell line L 5178 T.
Figure 2Evaluation of antiproliferative effect of chalcone 10 in combination with doxorubicin.
Figure 3Evaluation of antiproliferative effect of chalcone 14 in combination with doxorubicin.
Antiproliferative effects of chalcones 1–18 on L 5178 Y cells [μg/mL].
| Methoxylation pattern of ring A | ||||||
|
| 3′,4′,5′-a | 2′,3′,4′- | 2′,4′,6′- | 2′,4′- | 3′,4′- | 2′,5′- |
|
| ||||||
| N(CH3)2 | <0.19 | 0.42 ± 0.14 | ≫50 | 43.18 ± 1.48 | >50 | 0.47 ± 0.01 |
| Cl | 0.14 | 2.16 ± 0.00 | 5.19 ± 0.14 | 4.98 ± 0.33 | 2.17 ± 0.31 | 4.95 ± 0.12 |
| OCH3 | <0.19 | 2.23 ± 0.28 | 22.75 ± 3.90 | 42.58 ± 18.03 | 5.06 ± 0.89 | 1.74 ± 0.07 |
aThe antiproliferative activity of chalcones having 3′,4′,5′-trimethoxylated pattern was determined previously [8].
Figure 4Recognition patterns of chalcones 1–18 required for the interaction with P-gp.